|
Biological Activity:
Very potent and specific glycogen synthase kinase GSK-3 inhibitor; highly recommended tool.
References:
C Tong et al. Generating gene knockout rats by homologous recombination in embryonic stem cells. Nature Protocols 2011, 6, 827–844. [online]
M Kawamata and T Ochiya. Generation of genetically modified rats from embryonic stem cells. PNAS 2010, 107(32), 14223-14228. [online]
MY Chang et al. Direct Reprogramming of Rat Neural Precursor Cells and Fibroblasts into Pluripotent Stem Cells. PLoS One. 2010; 5(3): e9838. [online]
IM Aparicio et al. Identification and regulation of glycogen synthase kinase-3 during bovine embryo development. Reproduction 2010, 140, 83-92. [online]
B Zimmer et al. Coordinated waves of gene expression during neuronal differentiation of embryonic stem cells as basis for novel approaches to developmental neurotoxicity testing. Cell Death and Differentiation. 2011, 18, 383–395. [online] [full paper]
QL Ying et al. The ground state of embryonic stem cell self-renewal. Nature, 2008, 453, 519-523. [online][F1000 Biology]
J Bain et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 2007, 408, 297–315. [online Abstract]
DB Ring et al. Selective glycogen synthase kinase inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 2003, 52, 588–595. [online]
AS Wagman et al. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr Pharm Des 2004, 10, 1105–1137. [online]
Chemical Name: 6-{2-[4-(2,4-Dichloro-phenyl)-5-(4-methyl-1H-imidazol-2-yl)-pyrimidin-2-ylamino]-ethylamino}-nicotinonitrile
| 
